These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29254096)

  • 21. Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population.
    Lao PJ; Handen BL; Betthauser TJ; Mihaila I; Hartley SL; Cohen AD; Tudorascu DL; Bulova PD; Lopresti BJ; Tumuluru RV; Murali D; Mathis CA; Barnhart TE; Stone CK; Price JC; Devenny DA; Mailick MR; Klunk WE; Johnson SC; Christian BT
    Alzheimers Dement (Amst); 2017; 9():1-9. PubMed ID: 28603769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pattern of amyloid accumulation in the brains of adults with Down syndrome.
    Annus T; Wilson LR; Hong YT; Acosta-Cabronero J; Fryer TD; Cardenas-Blanco A; Smith R; Boros I; Coles JP; Aigbirhio FI; Menon DK; Zaman SH; Nestor PJ; Holland AJ
    Alzheimers Dement; 2016 May; 12(5):538-45. PubMed ID: 26362596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions.
    Klupp E; Förster S; Grimmer T; Tahmasian M; Yakushev I; Sorg C; Yousefi BH; Drzezga A
    Brain Connect; 2014 Jun; 4(5):371-83. PubMed ID: 24870443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.
    Rabinovici GD; Jagust WJ; Furst AJ; Ogar JM; Racine CA; Mormino EC; O'Neil JP; Lal RA; Dronkers NF; Miller BL; Gorno-Tempini ML
    Ann Neurol; 2008 Oct; 64(4):388-401. PubMed ID: 18991338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
    Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
    Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation.
    Roberts RO; Knopman DS; Cha RH; Mielke MM; Pankratz VS; Boeve BF; Kantarci K; Geda YE; Jack CR; Petersen RC; Lowe VJ
    J Nucl Med; 2014 May; 55(5):759-64. PubMed ID: 24652830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.
    Hartley SL; Handen BL; Devenny D; Mihaila I; Hardison R; Lao PJ; Klunk WE; Bulova P; Johnson SC; Christian BT
    Neurobiol Aging; 2017 Oct; 58():68-76. PubMed ID: 28715661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease.
    Adriaanse SM; Wink AM; Tijms BM; Ossenkoppele R; Verfaillie SC; Lammertsma AA; Boellaard R; Scheltens P; van Berckel BN; Barkhof F
    Brain Connect; 2016 Feb; 6(1):1-8. PubMed ID: 26414628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease.
    Terada T; Therriault J; Kang MS; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Poltronetti NM; Ottoy J; Arias JF; Bezgin G; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Eur J Neurol; 2022 May; 29(5):1324-1334. PubMed ID: 35007366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease.
    Wirth M; Bejanin A; La Joie R; Arenaza-Urquijo EM; Gonneaud J; Landeau B; Perrotin A; Mézenge F; de La Sayette V; Desgranges B; Chételat G
    Neurobiol Aging; 2018 Mar; 63():140-151. PubMed ID: 29203090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementia.
    Frings L; Spehl TS; Weber WA; Hüll M; Meyer PT
    J Nucl Med; 2013 Nov; 54(11):1909-14. PubMed ID: 24101684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly.
    Oh H; Habeck C; Madison C; Jagust W
    Hum Brain Mapp; 2014 Jan; 35(1):297-308. PubMed ID: 22965806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.